Skip to main content

WHO recommendation BioNtech Tozinameran/US FDA - COVID-19 mRNA vaccine (nucleoside modified)

WHO recommendation BioNtech Tozinameran/US FDA - COVID-19 mRNA vaccine (nucleoside modified)


Product Overview


Type:                           COVID-19 mRNA Vaccine


INN:                            Tozinameran


Trade name:               COMIRNATY


EUL holder:               BioNTech Manufacturing GmbH


Country:                     Germany


Responsible NRA:     Food and Drug Administration


Country:                     United States of America


 

WHO EUL recommendation


Effective date:             16 July 2021


 

Product description

Pharmaceutical Form:                   Concentrate for dispersion for injection


Dosage:                                            30 mcg


Presentation:                                   2 mL Vial


Number of doses:                            6 doses of 0.3 mL (after dilution)


Route of administration:                Intramuscular


Age indication:                                12 years and older


Shelf – life:                                       24 months     Storage temperature:   (-90°C to -60°C)      


Refrigeration Storage Time (2°C to 8°C):     10 weeks   


 Storage Time (-20°C to 15°C)​:          2 weeks within the 18 months shelf life


Short Term Storage (5°C to 3°C):      31 days within the 18 months shelf life


Vaccine Vial monitor (VVM):         None


Preservative:                                 None


Adjuvant:                                        None


Diluent:                                           Sodium Chloride Inj. USP 0.9%


Handling of opened multi-dose vials: 

WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.


Packaging description

Secondary Packaging: Carton holding 195 vials (1170 doses). Dimensions: 22.9 x 22.9 x 4.0 cm

Tertiary Packaging:                             

Insulated box containing 5 secondary cartons with a total of 975 vials (5850 doses). Dimensions: 40 X 40 X 56 cm
 

Cold Chain Volume: 1.8 cm3/dose      (in secondary packaging)






 

 

Product information


Pharmaceutical Form:                       Concentrate for dispersion for injection


Dosage:                                                30 mcg


Presentation:                                       2 mL Vial


Number of doses:                                6 doses of 0.3 mL


Route of administration:                    Intramuscular


Age indication:                                    12 years and older


Shelf – life:                                           12 months     Storage temperature: -90°C to -60°C


Refrigeration Storage Time (2°C to 8°C):     10 weeks


Freezer Storage Time (-25 °C to -15°C):        DO NOT STORE


Vaccine Vial monitor (VVM):              None


Preservative:                                      None


Adjuvant:                                              None


Diluent:                                                 N/A


Handling of opened multi-dose vials: 

WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.


Packaging description

Secondary Packaging: Carton holding 195 vials (1170 doses). Dimensions: 22.9 x 22.9 x 4.0 cm

Tertiary Packaging:                             

Insulated box containing 5 secondary cartons with a total of 975 vials (5850 doses). Dimensions: 40 X 40 X 56 cm

Cold Chain Volume: 1.8 cm3/dose      (in secondary packaging)


 

Product information



Drug Product - Manufacturing site


  • Pharmacia and Upjohn Company LLC, Kalamazoo, Michigan (Pfizer, Kalamazoo)

Pharmaceutical Form:                       Concentrate for dispersion for injection


Dosage:                                                10 mcg


Presentation:                                       2 mL Vial


Number of doses:                                10 doses of 0.2 mL (after dilution)


Route of administration:                    Intramuscular


Age indication:                                    Children  from 5 to 11 years


Shelf – life:                                           12 months     Storage temperature:     -90°C to -60°C


 Refrigeration Storage Time (2°C to 8°C):       10 weeks         


Freezer Storage Time (-25 °C to -15°C):           DO NOT STORE


Vaccine Vial monitor (VVM):            None


Preservative:                                    None


Adjuvant:                                            None


Diluent:                                               Sodium Chloride Inj USP 0.9%


Handling of opened multi-dose vials: 

WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.


 

Packaging description

Secondary Packaging:    Carton holding 195 vials (1170 doses). Dimensions: 22.9 x 22.9 x 4.0 cm
Tertiary Packaging: Insulated box containing 5 secondary cartons with a total of 975 vials (5850 doses). Dimensions: 40 X 40 X 56 cm
Cold Chain Volume:  1.8 cm3/dose      (in secondary packaging)

 

Product information


Drug Substance - Manufacturing sites​


BioNTech Manufacturing GmbH
An der Goldgrube 12, 55131 Mainz, Germany

Pfizer Andover ACMF
Wyeth BioPharma Division of Wyeth Pharmaceuticals, LLC. 1 Burtt Road Andover, MA 01810, United States


Drug Product - Manufacturing sites

Pharmacia & Upjohn Company LLC
7000 Portage Road Kalamazoo, MI 49001, United States

Hospira Inc., a Pfizer company
1776 Centennial Drive, McPherson, Kansas 67460, United States

Exelead, Inc.
6925 Guion Road, Indianapolis, IN 46268, United States

Exela Pharma Sciences, LLC, NC
320 Cooperative Way Lenoir, NC 28645 United States,  and
1245 Blowing Rock Blvd Lenoir, NC 28645 United States